The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can’t be removed with surgery, the company said. These patients have already received prior treatment and don’t have any good alternatives.
AstraZeneca, Daiichi drug gets broad tumor approval in US
Estimated read time
1 min read